Opinion

Video

Key Takeaways in HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP,Martin Dietrich, MD, PhD

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Related Content
Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Lung Cancer
December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC